Teleflex to participate at the European Association for Percutaneous Cardiovascular Interventions Course (EuroPCR) 2019 with ...
May 15 2019 - 6:30AM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies for critical care, urology and surgery,
coronary and peripheral interventions, will showcase its complex
PCI product portfolio, the Arrow® AC3 Optimus™ Intra-Aortic Balloon
Pump (IABP) and the newly acquired MANTA™ Vascular Closure Device
at the EuroPCR being held in Paris, France on May 21 – 24, 2019.
Teleflex offers a full line of products that give interventional
cardiologists the tools they need to handle routine and complex
cases, resulting in improved outcomes for patients. Cardiologists
worldwide rely on the quality and proven clinical effectiveness of
products, such as the GuideLiner® V3 Catheter, TrapLiner® Catheter,
Turnpike® Catheter, Twin-Pass® Torque Dual Access Catheter,
SuperCross® Microcatheter, and R350™ Guidewire.
At EuroPCR, Teleflex will showcase the MANTA™ Vascular Closure
Device indicated for closure of femoral arterial access sites while
reducing time to hemostasis following the use of 10-20F devices or
sheaths (12-25F OD) in endovascular catheterization procedures.
With the MANTA™ Device, clinicians and hospitals can achieve:
- Successful large bore closure with a device that is simple to
use and does not require pre-closure, saving valuable time during
the most delicate interventional procedures.
- Low complication rates for fast reliable biomechanical closure
with rapid hemostasis, potentially reducing costs.1a,b
- Reproducible results, inspiring confidence in achieving
successful closure.1c
Finally, Teleflex will continue presenting the Arrow® AC3
Optimus™ IABP. This device helps a weakened heart pump blood and
can deliver IABP therapy to a broad range of patients, even those
not previously considered candidates for IABP therapy. Clinicians
may use the pump on patients with severe arrhythmias or with heart
rates as high as 200 beats per minute.2, 3 The Arrow® AC3 Optimus™
IABP with third-generation AutoPilot® Mode uses proprietary
algorithms to address key clinical challenges and simplifies
delivery of IABP therapy.4
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, AC3 Optimus, AutoPilot,
Deknatel, GuideLiner, Hudson RCI, LMA, MANTA, Pilling, R350, Rüsch,
SuperCross, TrapLiner, Turnpike, Twin-Pass, UroLift, and Weck are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates, in the U.S. and/or other countries. © 2019 Teleflex
Incorporated. All rights reserved. MCI-2019-0314
References:
- Data on file at Teleflex. The SAFE MANTA IDE Clinical Trial:a.
MANTA™ Device demonstrated a time to hemostasis of 24 seconds
median time (65 seconds mean time) from deployment to hemostasis.
b. Rate of time to hemostasis for MANTA™ Device demonstrated from
deployment to hemostasis. c. Percutaneous vascular closure obtained
with the MANTA™ Device without the use of unplanned endovascular or
surgical intervention.Study sponsored by Teleflex Incorporated or
its affiliates.
- Schreuder J, Castiglioni A, Donelli A, et al.
Automatic intraaortic balloon pump timing using an intra beat
dicrotic notch prediction algorithm. Ann Thorac Surg.
2005;79(3):1017-1022. Study sponsored by Teleflex.
- Donelli A, Jansen JRC, Hoeksel B, et al. Performance of a
real-time dicrotic notch detection and prediction algorithm in
arrhythmic human aortic pressure signals. J Clin Monit.
2002;17(3-4):181-185. Study sponsored by Teleflex.
- Torracca, L. Overcoming electro-surgical inference in IABP
therapy with the combined use of AutoPilot and FiberOptix IAB
sensor signal. 2007. (Case report, data on file). Study sponsored
by Teleflex.
Source: Teleflex IncorporatedJake
ElguiczeTreasurer and Vice President, Investor
Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024